“Excellence in the performance, curative direction and participation of leading visitors has been rewarded with the inclusion of Searchlight in The Globe and Mail and Report on Business Top Growing Companies for a year in a row,” said Mark Nawacki, president and CEO of Searchlight Pharma. . ” We are very excited about the long-term Searchlight. With the recently announced advertising release of Addyi® (flibanserin), which is the first maximum non-unusual remedy for sexual disorder in women, and the planned launch next year of our oral combination Nextstellis contraceptive candidate®, which is based on exclusive local estrogen (E4), our cutting-edge line will continue to provide answers to the desires for unsatisfied wellness and fitness of Canadian women and their fitness care. our success, and we are proud that this has once been identified through The Globe and Mail and Report on Business and its development rating ing Canadian companies. “
